Timing of Sentinel Node Biopsy Independently Predicts DFS and OS in Clinical Stage I/II Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Timing of Sentinel Node Biopsy Independently Predicts Disease-Free and Overall Survival in Clinical Stage I-II Melanoma Patients: A Multicentre Study of the Italian Melanoma Intergroup (IMI)
Eur. J. Cancer 2020 Sep 01;137(xx)30-39, M Mandalà, F Galli, R Patuzzo, A Maurichi, S Mocellin, CR Rossi, E Rulli, M Montesco, P Quaglino, V Caliendo, V De Giorgi, B Merelli, C Caracò, D Piazzalunga, A Labianca, S Ribero, R Senetta, A Gianatti, B Valeri, D Massi, PA Ascierto, M SantinamiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.